GlobeNewswire 5/22/2019 argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company...

GlobeNewswire 5/2/2019 Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy...

GlobeNewswire 2/4/2019 argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

GlobeNewswire 12/15/2018 Annual Changes to the NASDAQ Biotechnology Index

GlobeNewswire 11/2/2018 Van Lanschot Kempen trading update: third quarter 2018

GlobeNewswire 10/25/2018 argenx reports third quarter 2018 financial results and provides business update

GlobeNewswire 10/9/2018 argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

GlobeNewswire 9/21/2018 argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million

GlobeNewswire 9/19/2018 Antibody Discovery Services and Platforms Market, 2028

GlobeNewswire 9/19/2018 argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering

GlobeNewswire 9/17/2018 argenx announces launch of proposed public offering in the United States

GlobeNewswire 9/17/2018 argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in prima...

GlobeNewswire 9/6/2018 argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment o...

GlobeNewswire 8/29/2018 argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efga...

GlobeNewswire 8/22/2018 argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-...

GlobeNewswire 8/9/2018 argenx to Present at 2018 Wedbush PacGrow Healthcare Conference

GlobeNewswire 8/2/2018 argenx reports second quarter business update and half-year 2018 financial results

GlobeNewswire 7/26/2018 argenx to host conference call & webcast to report second quarter business update and half year 201...

GlobeNewswire 7/24/2018 argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Jo...

GlobeNewswire 7/17/2018 argenx receives milestone payment from strategic collaboration with Shire

GlobeNewswire 6/28/2018 argenx receives second preclinical milestone payment under its development agreement with AbbVie

GlobeNewswire 6/27/2018 iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and T...